{"id":"cetuximab-induction","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Skin rash"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-15%","effect":"Hypomagnesemia"},{"rate":"5-10%","effect":"Hypokalemia"}]},"_chembl":{"chemblId":"CHEMBL1201577","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This mechanism of action is based on the role of EGFR in promoting cell proliferation and survival in various cancers. By blocking EGFR, cetuximab can inhibit tumor growth and induce apoptosis in cancer cells.","oneSentence":"Cetuximab is a monoclonal antibody that targets and binds to the epidermal growth factor receptor (EGFR), preventing its activation and subsequent signaling.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:50:20.914Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer"},{"name":"Head and neck cancer"}]},"trialDetails":[{"nctId":"NCT07286149","phase":"PHASE1, PHASE2","title":"A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-23","conditions":"Lung Neoplasm Malignant","enrollment":190},{"nctId":"NCT06984861","phase":"PHASE2","title":"A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-05-13","conditions":"Oropharyngeal Carcinoma","enrollment":74},{"nctId":"NCT05491512","phase":"PHASE2","title":"A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-08-04","conditions":"HPV, Throat Cancer, Oropharyngeal Carcinoma","enrollment":121},{"nctId":"NCT04290546","phase":"PHASE1","title":"CIML NK Cell in Head & Neck Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-07-20","conditions":"Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":11},{"nctId":"NCT07404527","phase":"NA","title":"Bioelectrical Impedance Analysis for Perioperative Fluid Evaluation in Colorectal Cancer Surgery","status":"RECRUITING","sponsor":"Institute of Oncology Ljubljana","startDate":"2023-10-24","conditions":"Gastrointestinal Cancer, Digestive System Neoplasms","enrollment":60},{"nctId":"NCT04229459","phase":"PHASE2","title":"Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baruch Brenner","startDate":"2020-02-16","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":12},{"nctId":"NCT07094893","phase":"PHASE4","title":"Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2026-04-15","conditions":"Colorectal Cancer","enrollment":280},{"nctId":"NCT06332079","phase":"PHASE2","title":"Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients","status":"TERMINATED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2024-03-13","conditions":"Colorectal Cancer Metastatic","enrollment":4},{"nctId":"NCT06540326","phase":"PHASE2","title":"Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-11-12","conditions":"Colorectal Cancer Metastatic","enrollment":100},{"nctId":"NCT01154920","phase":"PHASE2","title":"Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-07-09","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":128},{"nctId":"NCT04009681","phase":"PHASE1, PHASE2","title":"A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)","status":"TERMINATED","sponsor":"Synthorx, Inc, a Sanofi company","startDate":"2019-06-20","conditions":"Metastasis","enrollment":175},{"nctId":"NCT05271604","phase":"PHASE2","title":"A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"BioAtla, Inc.","startDate":"2022-12-13","conditions":"Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck","enrollment":42},{"nctId":"NCT04722523","phase":"PHASE1","title":"A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-01-20","conditions":"Head and Neck Cancer, Head Cancer, Head Cancer Neck","enrollment":40},{"nctId":"NCT06856187","phase":"PHASE2","title":"Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-02-28","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":119},{"nctId":"NCT00665392","phase":"PHASE2","title":"Cetuximab and Combination Chemotherapy in Patients With Stage III-IV Resectable Oropharynx Cancer","status":"COMPLETED","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2008-02-01","conditions":"Head and Neck Cancer","enrollment":42},{"nctId":"NCT07015333","phase":"","title":"Case Review of Patients With Betel Nut-induced Oral Cancer Treated With Pembrolizumab and Cetuximab","status":"COMPLETED","sponsor":"Commonwealth Healthcare Corporation","startDate":"2020-03-01","conditions":"Oral Squamous Cell Carcinoma (OSCC)","enrollment":31},{"nctId":"NCT06005324","phase":"PHASE1","title":"Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2023-12-18","conditions":"HPV-Negative Squamous Cell Carcinoma","enrollment":36},{"nctId":"NCT07000305","phase":"PHASE2","title":"A Study of Cetuximabβ Combined With Envolimab and mFOLFOX6 in Subjects With Advanced Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tao Zhang","startDate":"2025-05-20","conditions":"Advanced Colorectal Cancer","enrollment":42},{"nctId":"NCT01393821","phase":"NA","title":"Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2012-01-23","conditions":"Dermatologic Complications, Malignant Neoplasm, Pain","enrollment":27},{"nctId":"NCT05217069","phase":"PHASE2","title":"FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2019-09-27","conditions":"Treatment Related Cancer","enrollment":57},{"nctId":"NCT06715501","phase":"NA","title":"Efficacy and Safety of Cadonilimab and Chemoradiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma","status":"ENROLLING_BY_INVITATION","sponsor":"First Affiliated Hospital of Ningbo University","startDate":"2024-12-01","conditions":"Locally Advanced Esophageal Squamous Cell Carcinoma, II-IIIB Stages","enrollment":20},{"nctId":"NCT06521866","phase":"PHASE2","title":"Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-03-01","conditions":"Advanced Colorectal Carcinoma, Immunotherapy","enrollment":208},{"nctId":"NCT06869473","phase":"PHASE2","title":"Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2025-02-20","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC), Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer","enrollment":67},{"nctId":"NCT06640725","phase":"PHASE2","title":"Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&N","status":"RECRUITING","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2025-01-02","conditions":"Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck","enrollment":70},{"nctId":"NCT04513951","phase":"PHASE2","title":"AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients","status":"COMPLETED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2020-04-01","conditions":"Metastatic Colorectal Cancer","enrollment":62},{"nctId":"NCT02573493","phase":"PHASE2","title":"Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2016-04-13","conditions":"Squamous Cell Carcinoma of the Head and Neck, Carcinoma, Squamous Cell of the Head and Neck, Cancer of Head and Neck","enrollment":96},{"nctId":"NCT06714266","phase":"PHASE2","title":"Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2024-12-15","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":30},{"nctId":"NCT03009058","phase":"PHASE1, PHASE2","title":"Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer","status":"TERMINATED","sponsor":"Immodulon Therapeutics Ltd","startDate":"2017-05-31","conditions":"Metastatic Cancer","enrollment":2},{"nctId":"NCT06207656","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","startDate":"2024-04-16","conditions":"Colorectal Cancer","enrollment":70},{"nctId":"NCT00868491","phase":"PHASE2","title":"Induction Chemotherapy Followed by Chemoradiation With Cetuximab in Head and Neck Cancer","status":"COMPLETED","sponsor":"Institute of Oncology Ljubljana","startDate":"2008-03","conditions":"Head and Neck Cancer","enrollment":30},{"nctId":"NCT03164655","phase":"PHASE2","title":"Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2018-07-25","conditions":"Colorectal Cancer Metastatic","enrollment":20},{"nctId":"NCT06616259","phase":"PHASE3","title":"First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study","status":"NOT_YET_RECRUITING","sponsor":"Meng Qiu","startDate":"2024-09-26","conditions":"Colorectal Cancer (CRC), Capecitabine, Cetuximab","enrollment":452},{"nctId":"NCT03387111","phase":"PHASE1, PHASE2","title":"QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2018-01-09","conditions":"Squamous Cell Carcinoma","enrollment":4},{"nctId":"NCT02291289","phase":"PHASE2","title":"A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-04-17","conditions":"Colorectal Cancer","enrollment":1044},{"nctId":"NCT06151743","phase":"PHASE2","title":"Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2024-01-18","conditions":"Locally Advanced Hypopharyngeal Carcinoma","enrollment":32},{"nctId":"NCT01588431","phase":"PHASE2","title":"Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2011-12","conditions":"Carcinoma, Squamous Cell of Head and Neck","enrollment":3},{"nctId":"NCT00502463","phase":"NA","title":"Induction Chemotherapy Prior to Radio-immunotherapy in Head and Neck Cancer Stage III/IV - a Methodical Trial","status":"COMPLETED","sponsor":"Austrian South Oncology Group","startDate":"2007-10-03","conditions":"Head and Neck Cancer","enrollment":51},{"nctId":"NCT02624128","phase":"PHASE2","title":"Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck","status":"UNKNOWN","sponsor":"National Cancer Institute, Naples","startDate":"2015-02-23","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":39},{"nctId":"NCT06118047","phase":"PHASE2","title":"Crisaborole Ointment for Skin Toxicity Induced by Cetuximab","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2023-08-01","conditions":"Metastatic Colorectal Cancer, Cetuximab, Skin Toxicity","enrollment":33},{"nctId":"NCT06081582","phase":"PHASE2","title":"Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2023-07-06","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":33},{"nctId":"NCT06035133","phase":"NA","title":"Treatment of Low Locally Advanced Rectal Cancer With Radiotherapy Removal TNT Plus Neoadjuvant Therapy","status":"NOT_YET_RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2023-11-10","conditions":"Rectal Cancer","enrollment":213},{"nctId":"NCT04262635","phase":"PHASE3","title":"Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2021-09-24","conditions":"Colorectal Cancer","enrollment":80},{"nctId":"NCT00089297","phase":"PHASE2","title":"Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2005-01-06","conditions":"Head and Neck Cancer","enrollment":74},{"nctId":"NCT01084083","phase":"PHASE2","title":"Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2010-08-11","conditions":"Head and Neck Cancer, Precancerous Condition","enrollment":90},{"nctId":"NCT05872880","phase":"","title":"TPExtreme Induced Chemotherapy Followed by Surgery and Radiotherapy in the Oral Carcinoma.","status":"RECRUITING","sponsor":"Xiangya Hospital of Central South University","startDate":"2022-04-01","conditions":"Oral Squamous Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma","enrollment":124},{"nctId":"NCT03115567","phase":"PHASE2","title":"A Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2017-02-16","conditions":"Acneiform Rash, Papulopustular Eruption","enrollment":14},{"nctId":"NCT01416688","phase":"","title":"S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2011-11-15","conditions":"Colorectal Cancer, Dermatologic Complications, Lung Cancer","enrollment":146},{"nctId":"NCT01874860","phase":"PHASE2","title":"Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients","status":"COMPLETED","sponsor":"University of Louisville","startDate":"2013-08","conditions":"Colorectal Cancer, Head and Neck Cancer","enrollment":24},{"nctId":"NCT02627274","phase":"PHASE1","title":"A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-12-07","conditions":"Solid Tumor, Breast Cancer, Cancer of Head and Neck","enrollment":134},{"nctId":"NCT01884259","phase":"PHASE2","title":"Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN","status":"COMPLETED","sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","startDate":"2013-05","conditions":"Squamous Cell Carcinoma of the Hypopharynx Stage III, Squamous Cell Carcinoma of the Hypopharynx Stage IV, Squamous Cell Carcinoma of the Larynx Stage III","enrollment":100},{"nctId":"NCT04508816","phase":"PHASE2","title":"Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy","status":"COMPLETED","sponsor":"Fudan University","startDate":"2016-01-01","conditions":"Nasopharyngeal Carcinoma","enrollment":45},{"nctId":"NCT04508829","phase":"PHASE2","title":"Anti-EGFR Therapy With IMRT Concurrent Chemoradiotherapy in Locally Advanced OPC Resistant to Induction Chemotherapy","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2016-01-01","conditions":"Oropharyngeal Carcinoma","enrollment":52},{"nctId":"NCT04872634","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor Treatment","status":"UNKNOWN","sponsor":"NKMAX Co., Ltd.","startDate":"2021-07-08","conditions":"Non-small Cell Lung Cancer","enrollment":24},{"nctId":"NCT02942706","phase":"PHASE2, PHASE3","title":"Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2021-11","conditions":"Colorectal Cancer","enrollment":200},{"nctId":"NCT03563170","phase":"PHASE1, PHASE2","title":"QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-05-25","conditions":"Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent","enrollment":""},{"nctId":"NCT01412229","phase":"PHASE2","title":"Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2012-02","conditions":"Head and Neck Cancer","enrollment":40},{"nctId":"NCT01094444","phase":"PHASE2","title":"Investigation of the Effect of Vitamin K3-lotion for the Treatment of Cetuximab Induced Folliculitis","status":"COMPLETED","sponsor":"Per Pfeiffer","startDate":"2010-05","conditions":"Folliculitis","enrollment":30},{"nctId":"NCT01326923","phase":"PHASE2","title":"Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer","status":"TERMINATED","sponsor":"Louisiana State University Health Sciences Center Shreveport","startDate":"2010-06","conditions":"Head and Neck Squamous Cell Cancer","enrollment":7},{"nctId":"NCT01566435","phase":"PHASE2","title":"Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck Cancer","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2012-08-09","conditions":"Head and Neck Neoplasms","enrollment":30},{"nctId":"NCT00736944","phase":"PHASE2","title":"Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2008-12-19","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":30},{"nctId":"NCT01133678","phase":"PHASE2","title":"Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck","status":"TERMINATED","sponsor":"University of Chicago","startDate":"2010-05-04","conditions":"Head and Neck Cancer","enrollment":50},{"nctId":"NCT01440270","phase":"PHASE2","title":"Neo-adjuvant Erbitux-based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2011-08","conditions":"Locally Advanced Malignant Neoplasm, Oral Cancer, Oropharyngeal Carcinoma","enrollment":145},{"nctId":"NCT00721513","phase":"PHASE2","title":"Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2008-09","conditions":"Head and Neck Cancer","enrollment":20},{"nctId":"NCT01317433","phase":"NA","title":"Pre-emptive Cycline Treatment on Cetuximab Induced Skin Toxicity in Colorectal Cancer","status":"TERMINATED","sponsor":"Institut Cancerologie de l'Ouest","startDate":"2010-12-29","conditions":"Colorectal Cancer Metastatic, Skin Toxicity","enrollment":25},{"nctId":"NCT01254617","phase":"PHASE1","title":"Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-02-10","conditions":"Recurrent Colon Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma","enrollment":24},{"nctId":"NCT04160416","phase":"PHASE2","title":"mXELOXIRI Combined With Molecular Targeted Drug in mCRC","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2019-07-01","conditions":"Unresectable Metastatic Colorectal Cancer","enrollment":48},{"nctId":"NCT00468169","phase":"PHASE2","title":"Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2006-07","conditions":"Head and Neck Cancer","enrollment":110},{"nctId":"NCT01230476","phase":"PHASE2","title":"Induction and Concurrent Chemoradiotherapy With Cetuximab for Patients With Locally Advanced Nasopharyngeal Carcinoma","status":"TERMINATED","sponsor":"University of Malaya","startDate":"2010-05","conditions":"Nasopharyngeal Carcinoma","enrollment":3},{"nctId":"NCT03923036","phase":"","title":"Anticancer Vigilance Of Cardiac Events (AVOCETTE) in Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"University Hospital, Caen","startDate":"2019-04","conditions":"Colorectal Cancer Metastatic","enrollment":2000},{"nctId":"NCT03485638","phase":"","title":"Assessment and Prediction of Cetuximab-Induced Hypersensitivity Reactions Using Cetuximab Specific IgE Detection","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2016-11-04","conditions":"Tumor Disease Including Colorectal Cancer, Head & Neck Squamous Cell Carcinoma","enrollment":400},{"nctId":"NCT01181401","phase":"PHASE2","title":"InductionChemo-Radio-Antibody-Treatment","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2010-08","conditions":"Squamous Cell Carcinoma of the Head, Squamous Cell Carcinoma of the Neck","enrollment":94},{"nctId":"NCT01233843","phase":"PHASE3","title":"Chemoradiotherapy HNSCC, Randomized Study, Docetaxel,Cisplatin, 5FU,Erbitux.","status":"COMPLETED","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2009-05-18","conditions":"Squamous Cell Head and Neck Carcinoma","enrollment":370},{"nctId":"NCT01540344","phase":"PHASE2","title":"Combined Anticancer Treatment of Advanced Colon Cancer","status":"TERMINATED","sponsor":"University of Regensburg","startDate":"2010-10","conditions":"Peritoneal Carcinomatosis, Colorectal Cancer Metastatic","enrollment":26},{"nctId":"NCT03529279","phase":"PHASE3","title":"CNG Staging Compared With 8th UICC of NPC for Treatment Decision-marking and Selection of Chemotherapy and Radiotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2018-06-12","conditions":"Nasopharyngeal Carcinoma","enrollment":1324},{"nctId":"NCT01221753","phase":"PHASE2","title":"Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2011-07","conditions":"Squamous Cell Carcinoma of the Head and Neck, Human Papilloma Virus","enrollment":7},{"nctId":"NCT02298595","phase":"PHASE1, PHASE2","title":"Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma","status":"WITHDRAWN","sponsor":"Julie E. Bauman, MD, MPH","startDate":"2016-08","conditions":"Carcinoma, Squamous, Squamous Cell Carcinoma, Oropharyngeal Neoplasms","enrollment":""},{"nctId":"NCT01693159","phase":"NA","title":"Effects of ECA on Quality of Life in Head and Neck Cancer Patients Suffering From Cetuximab-induced Rhagades","status":"UNKNOWN","sponsor":"National Center for Tumor Diseases, Heidelberg","startDate":"2011-05","conditions":"Pain","enrollment":50},{"nctId":"NCT00985855","phase":"PHASE2","title":"Feasibility of Cetuximab Associated With Concomitant Radio-Chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Institut de Cancérologie de la Loire","startDate":"2009-09","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":91},{"nctId":"NCT00999700","phase":"PHASE3","title":"Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin","status":"UNKNOWN","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2009-09","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":282},{"nctId":"NCT01434394","phase":"PHASE2, PHASE3","title":"Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2011-08","conditions":"Locally Advanced Malignant Neoplasm, Oral Cancer, Oropharyngeal Carcinoma","enrollment":243},{"nctId":"NCT01326559","phase":"PHASE2","title":"Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Concurrence With Intensity-modulated Radiotherapy for Local Recurrent Nasopharyngeal Carcinoma (NPC)","status":"COMPLETED","sponsor":"Hong Kong Nasopharyngeal Cancer Study Group Limited","startDate":"2010-06","conditions":"Nasopharyngeal Carcinoma","enrollment":33},{"nctId":"NCT00226239","phase":"PHASE2","title":"Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2005-10","conditions":"Cancer","enrollment":39},{"nctId":"NCT01895257","phase":"PHASE3","title":"Comparing HAI-90Y (SIR-spheres)+Chemotx LV5FU2 Versus Chemotx LV5FU2 Alone to Treat Colorectal Cancer","status":"UNKNOWN","sponsor":"Universiteit Antwerpen","startDate":"2013-08","conditions":"Colorectal Cancer","enrollment":162},{"nctId":"NCT01256437","phase":"PHASE2","title":"Evaluating Preventive Therapy With Oint Threolone, Synthomycine or Aqua Cream, for EGFR'I Induced Acneiform Rash","status":"COMPLETED","sponsor":"Rabin Medical Center","startDate":"2011-01","conditions":"Acneiform Rash","enrollment":90},{"nctId":"NCT01467115","phase":"PHASE2","title":"Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer","status":"COMPLETED","sponsor":"Drexel University College of Medicine","startDate":"2010-03","conditions":"Head and Neck Cancer","enrollment":1},{"nctId":"NCT00091247","phase":"NA","title":"Tetracycline in Preventing Skin Rash in Patients Who Are Receiving Drugs Such as Gefitinib and Cetuximab for Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2004-12","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":130},{"nctId":"NCT01931150","phase":"PHASE3","title":"Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-08","conditions":"Cetuximab-induced Papulopustular (Acneiform) Rash Who Have, Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma","enrollment":11},{"nctId":"NCT00362986","phase":"PHASE3","title":"Topical Sunscreen in Preventing Skin Rash in Patients Receiving Drugs Such as Erlotinib or Cetuximab for Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2006-10","conditions":"Dermatologic Complications, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":116},{"nctId":"NCT02978313","phase":"PHASE2, PHASE3","title":"Cetuximab Monotherapy Maintenance Treatment in mCRC","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2016-11","conditions":"Colorectal Cancer","enrollment":500},{"nctId":"NCT01050426","phase":"PHASE2","title":"A Clinical Study of UFT/Leucovorin, Radiotherapy With or Without Cetuximab Following Induction Gemcitabine Plus Capecitabine in Patients With Locally Advanced Pancreatic Cancer (PERU)","status":"TERMINATED","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2009-03","conditions":"Pancreatic Cancer","enrollment":17},{"nctId":"NCT02633176","phase":"PHASE3","title":"Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-01","conditions":"Nasopharyngeal Carcinoma","enrollment":120},{"nctId":"NCT00857246","phase":"PHASE2","title":"Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2005-07","conditions":"Gastric Cancer, Stomach Cancer","enrollment":30},{"nctId":"NCT00599131","phase":"PHASE2","title":"Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)","status":"TERMINATED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2007-08","conditions":"Cancer of Larynx","enrollment":4},{"nctId":"NCT00368992","phase":"PHASE2","title":"S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-08","conditions":"Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer","enrollment":110},{"nctId":"NCT00867009","phase":"PHASE2","title":"A Study of Induction and Maintenance Treatment of Advanced or Metastatic Non Squamous Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-04","conditions":"Non-Small-Cell Lung Cancer","enrollment":113},{"nctId":"NCT00508664","phase":"PHASE2","title":"Docetaxel, Cisplatin (TP) + Radiation +/- Cetuximab in Larynx Carcinoma (CA)","status":"COMPLETED","sponsor":"ClinAssess","startDate":"2007-07","conditions":"Squamous Cell Carcinoma of the Hypopharynx, Larynx Carcinoma","enrollment":180},{"nctId":"NCT01228565","phase":"PHASE3","title":"Trial of OTD70DERM® in Radio-dermatitis Induced by Radiotherapy-Erbitux®","status":"COMPLETED","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2010-08","conditions":"Head and Neck Carcinoma","enrollment":76},{"nctId":"NCT02295930","phase":"PHASE2","title":"Induction Chemoterapy With Folfoxiri Plus Cetuxumab in Unresectable Colorectal Cancer Patient","status":"COMPLETED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2011-10","conditions":"Metastatic Colorectal Cancer","enrollment":143},{"nctId":"NCT00735345","phase":"PHASE2","title":"Chemotherapy Induction and Chemoradiotherapy in Patients With Esophageal Carcinoma","status":"TERMINATED","sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","startDate":"2008-08","conditions":"Esophageal Cancer","enrollment":50},{"nctId":"NCT01086826","phase":"PHASE3","title":"Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"Associazione Volontari Pazienti Oncologici","startDate":"2008-03","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":320}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Erbitux"],"phase":"phase_2","status":"active","brandName":"Cetuximab Induction","genericName":"Cetuximab Induction","companyName":"Arbeitsgemeinschaft medikamentoese Tumortherapie","companyId":"arbeitsgemeinschaft-medikamentoese-tumortherapie","modality":"Biologic","firstApprovalDate":"","aiSummary":"Cetuximab is a monoclonal antibody that targets and binds to the epidermal growth factor receptor (EGFR), preventing its activation and subsequent signaling. Used for Colorectal cancer, Head and neck cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}